These agents have been developed against a variety of target-kinases other than (or in addition to) RET, such as VEGF receptors, AXL, FGFR1, EGFR, MET, c-KIT and BRAF, and unfortunately demonstrated limited potency for RET-positive cancers. Here, MET is linked to cancer.